Cel Sci Corporation New (CVM)

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international...

Form 8-K - Current report

CEL-SCI Announces Closing of Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing...

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

U.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of...

Form 424B5 - Prospectus [Rule 424(b)(5)]

CEL-SCI Corporation Announces Pricing of Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing...

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030 Senior Saudi Government, Investment and Healthcare Leaders to Attend...

Form RW - Registration Withdrawal Request

Form 4 - Statement of changes in beneficial ownership of securities

CEL-SCI Reports Fiscal Second Quarter 2026 Results

On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

CEL-SCI Announces Closing of Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing...

Form EFFECT - Notice of Effectiveness